Get started
Author

Charu Kothari

The Importance of Breast Adipose Tissue in Breast Cancer
2020 · Charu Kothari, Caroline Diorio, et al. · International Journal of Molecular Sciences · 170
PDF
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2016 · Nandini Verma, Anna-Katharina Müller, et al. · Cancer Research · 75
PDF
Community acquisition of β-lactamase producing Enterobacteriaceae in neonatal gut
2013 · Charu Kothari, Rajni Gaind, et al. · BMC Microbiology · 53
PDF
Machine learning analysis identifies genes differentiating triple negative breast cancers
2020 · Charu Kothari, Mazid Abiodoun Osseni, et al. · Scientific Reports · 50
PDF
Identification of a gene signature for different stages of breast cancer development that could be used for early diagnosis and specific therapy
2018 · Charu Kothari, Geneviève Ouellette, et al. · Oncotarget · 33
PDF
VEB-1 extended-spectrum β-lactamase-producing multidrug-resistant Proteus mirabilis sepsis outbreak in a neonatal intensive care unit in India: clinical and diagnostic implications
2016 · Sarika Jain, Rajni Gaind, et al. · JMM Case Reports · 23
High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve neonates: a study from India
2018 · Rushika Saksena, Rajni Gaind, et al. · Journal of Medical Microbiology · 21
TBC1D9: An Important Modulator of Tumorigenesis in Breast Cancer
2021 · Charu Kothari, Alisson Clemenceau, et al. · Cancers · 20
PDF
Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?
2021 · Charu Kothari, Alisson Clemenceau, et al. · Cancers · 19
PDF
ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
2023 · Julia O’Sullivan, Charu Kothari, et al. · Nucleic Acids Research · 15
The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
2023 · Adèle Beneyton, Louis Nonfoux, et al. · NAR Cancer · 13
PDF
Gene Signatures of Breast Cancer Development and the Potential for Novel Targeted Treatments
2020 · Charu Kothari, Caroline Diorio, et al. · Pharmacogenomics · 10
PDF
Transcriptional signature of lymphoblastoid cell lines ofBRCA1,BRCA2and non-BRCA1/2high risk breast cancer families
2017 · Marie-Christine Pouliot, Charu Kothari, et al. · Oncotarget · 9
Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2020 · Nandini Verma, Anna-Katharina Müller, et al. · Cancer Research · 1
Data from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure S2 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Material and Methods from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure Legends from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure S1 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure S4 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Table S2 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Table S1 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Figure S3 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
Supplementary Table S1 from Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
2023 · Nandini Verma, Anna-Katharina Müller, et al.
PDF
Works count: 33
Citation count: 512
H-index: 11
I10-index: 12
Year
Topic
Type